Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Cash from Financing Activities: 2022-2023

Historic Cash from Financing Activities for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to $100.1 million.

  • Lexeo Therapeutics' Cash from Financing Activities rose 123644.44% to $100.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $103.8 million, marking a year-over-year change of. This contributed to the annual value of $88.8 million for FY2024, which is 14.47% down from last year.
  • Latest data reveals that Lexeo Therapeutics reported Cash from Financing Activities of $100.1 million as of Q4 2023, which was up 2,458.05% from $3.9 million recorded in Q3 2023.
  • In the past 5 years, Lexeo Therapeutics' Cash from Financing Activities registered a high of $100.1 million during Q4 2023, and its lowest value of -$98,000 during Q1 2023.
  • Its 2-year average for Cash from Financing Activities is $20.7 million, with a median of -$81,000 in 2022.
  • Data for Lexeo Therapeutics' Cash from Financing Activities shows a peak YoY soared of 123,644.44% (in 2023) over the last 5 years.
  • Quarterly analysis of 2 years shows Lexeo Therapeutics' Cash from Financing Activities stood at -$81,000 in 2022, then soared by 123,644.44% to $100.1 million in 2023.
  • Its Cash from Financing Activities was $100.1 million in Q4 2023, compared to $3.9 million in Q3 2023 and -$94,000 in Q2 2023.